Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.7.4.9 extracted from

  • Sato, T.; Neschadim, A.; Konrad, M.; Fowler, D.H.; Lavie, A.; Medin, J.A.
    Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy (2007), Mol. Ther., 15, 962-970.
    View publication on PubMed

Application

Application Comment Organism
medicine enzyme/prodrug combination for selectively inducing apoptosis in lentiviral vector-transduced cells, based on designed variants of human thymidylate kinase that effectively phosphorylate 3'-azido-3'-deoxythymidine. Mechanism involves apoptosis induction via disruption of the inner membrane potential and activation of caspase-3. Low-dose 3'-azido-3'-deoxythymidine administration to non-obese diabetic/severe combined immunodeficiency mice injected with the engineered cells suppresses tumor growth Homo sapiens

Protein Variants

Protein Variants Comment Organism
additional information engineering of enzyme/prodrug combinations for selectively inducing apoptosis in lentiviral vector-transduced cells, based on designed variants of human thymidylate kinase that effectively phosphorylate 3'-azido-3'-deoxythymidine. Recombinant lentiviral vector constructs contain either mutant F105Y of human thymidylate kinase or mutant R16G that additionally displays an exchange of 11 amino acids residues of wild-type with 13 residues from the Escherichia coli orthologue. In addition, they contain human CD19 lacking its cytoplasmic tail Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-